‘It’s A Great Opportunity But It’s Also Late’ – Samsung Bioepis’ Woollett On Biosimilar Streamlining
Regulatory Expert Also Discusses Economic Challenges And Access
Samsung Bioepis’ Gillian Woollett discusses the global implications of biosimilar streamlining (Shutterstock) 
